ISRCTN44977207暂停未知
Personalised ultraviolet B (UVB) treatment of psoriasis through biomarker integration with computational modelling of psoriatic plaque resolution
ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 135 人开始时间: 2020年5月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 years or older (no upper age limit)
- •2. Able to speak English
- •3. Able to provide informed consent
- •4. Has chronic plaque psoriasis
- •5. Prescribed NbUVB phototherapy
- •6. Able and willing to attend the phototherapy department regularly
排除标准
- •1. Able to control their psoriasis or already controlled by topical therapy
- •2. Pregnant
- •3. Have had significant sun exposure, sun-bed use or previous NbUVB within the last month or be planning significant sun exposure or sun-bed use in the next month
- •4. Have previously taken, in the last three months any of the following: methotrexate, azathioprine, ciclosporin, biological therapy or systemic steroids for treatment of psoriasis
- •5. Have previously taken, in the last month, any oral photosensitising medications, including: thiazide diuretics, antibiotics such as tetracyclines and quinolones, non-steroidal anti-inflammatory drugs, phenothiazines, retinoids, sulphonylureas, quinine and St John’s Wort
- •6. Also suffer from diseases where phototherapeutic treatment is contraindicated: xeroderma pigmentosum, lupus erythematosus
研究者
相似试验
招募中
1 期
Targeted broadband UV-B phototherapy in pityriasis albaCTRI/2017/12/010882IADV50
招募中
不适用
arrowband ultraviolet B phototherapy for patients with uremic pruritusDiseases of the skin and subcutaneous tissueKCT0003701Kangdong Sacred Heart Hospital34
已完成
不适用
Effect of narrowband ultraviolet B therapy on serum levels of CD26/dipeptidyl-peptidase IV and truncated form of substance P in plaque-type psoriasisitch in psoriasisCD26/DPPIV,Narrowband UVB,Pruritus,Psoriasis,Substance PTCTR20190709005The National Research Council of Thailand13
进行中(未招募)
不适用
arrow band UV-B phototherapy and fluticasone proprionate versus narrow band UV-B phototherapy and placebo for the treatment of active vitiligo: a randomized double blind controlled trial - UVBVITarrow band ultra violet B phototherapy is the gold standard for the treatment of vitiligo vulgaris. Ultra violet A and fluticasone proprionate (cutivate) together have shown significant better repigmentation than both treatments alone in a study by Westerhof et al in 1999. We expect that the combination of narrow band ultra violet B and fluticasone proprionate will have a significantly better result in terms of repigmentation for the treatment of vitiligo.EUCTR2008-006903-22-NLAcademic Medical Center
招募中
1 期
The use of ultraviolet light photochemotherapy Polarised Ultra Violet A [PUVA] in the oral cavity in conjunction with a oral photo-sensitiser [5-methoxypsolaren or 8-methoxypsoralen] for oral graft-versus- host disease [GVHD] in allogeneic bone marrow transplant patients [ABMT].Chronic Oral Graft versus Host DiseaseBlood - Haematological diseasesACTRN12613000330741St Vincent's Hospital, Sydney25
